MONTRÉAL, Nov. 18 /CNW Telbec/ - Canada's Research-Based Pharmaceutical Companies (Rx&D) is pleased to announce the appointment of Mr. Paul Lévesque, President of Pfizer Canada Inc. as Chair of the association's Board of Directors. Mr. Lévesque assumed the Board leadership at Rx&D's Annual General meeting held in Montréal today.
Mr. Lévesque is a member of Rx&D's Executive Committee and Board of Directors. Before becoming Board Chair, he served on several industry committees and, more recently, as Chair of the Federal Affairs Committee.
"This is a time of significant change in our industry," said Paul Lévesque. "I take on this role recognizing that the future of our industry lies with our ability to create a knowledge-based economy that fosters research and innovation. Our membership has a role to play in this area by being a catalyst for innovation, whose effects can be felt across all levels of the life science sector. During my term, I will proactively initiate discussions with governments in order to create solutions for our common challenges and also to ensure access to innovative medicines for all Canadians."
Mr. Lévesque has 25 years of varied experience in the pharmaceutical industry. He started in 1985 when he joined Upjohn Canada before moving to Pfizer Canada in 1992 as a product manager. Mr. Lévesque then moved through various marketing positions while working on launching numerous important, innovative medicines.
In 2000, Paul Lévesque became the first Vice-President of Marketing for Pfizer Canada before moving to Paris, France in 2002 to take a similar position in the company. He held that position until his appointment to his current role in January 2007.
Born in Quebec City, Mr. Lévesque holds a B.Sc. in biochemistry from Laval University, Quebec City and a Diploma in Management from McGill University, Montreal. Mr. Lévesque also gives back to the community. He is the Interim President of the Board of Directors of Montreal in Vivo, and serves on several other Boards of Directors, such as the Canadian Council for Research in Disease Management (CCRDM), the Quebec Consortium for Drug Discovery (CQDM), and the Advanced Coronary Treatment Foundation (ACT) in Ottawa, to name a few.
"We are proud to welcome Mr. Lévesque as Chair of the Rx&D Board of Directors," said Rx&D President Russell Williams. "He is a keen advocate of the importance of access to innovative medicines and vaccines in our health-care system and he firmly believes in building the knowledge-based economy for Canada. His Canadian and international experience will help the association move Canada's innovation agenda forward," said Mr. Williams.
Rx&D is an association of leading research-based pharmaceutical companies dedicated to improving the health of all Canadians through the discovery and development of new medicines and vaccines. Our community represents 18,000 men and women working for close to 50 member companies and invests more than $1 billion in research and development each year to fuel Canada's knowledge-based economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.
SOURCE Canada's Research-Based Pharmaceutical Companies (Rx&D)
For further information: For further information: François Lessard, Communications, Telephone: (613) 236-0455, E-mail: firstname.lastname@example.org